Pemvidutide Cuts Heavy Drinking Days in Phase 2 AUD Trial; FDA Meeting Set for December
ALT is trading near its 52-week low of $1.91 (12% above the low).
Summary
Altimmune presented full RECLAIM Phase 2 data in alcohol use disorder at AASLD, showing pemvidutide cut heavy drinking days per week by 4.20 versus 2.75 for placebo (p=0.0014), with 42.2% of treated patients reaching zero heavy drinking days versus 17.4% on placebo. The PEth biomarker fell 153.4 ng/mL on drug while rising 22.0 ng/mL on placebo, and patients lost 8.7% of body weight versus a 0.4% gain. Tolerability was manageable: GI side effects were mostly mild-to-moderate and discontinuation rates were comparable (20% vs 22%). The company will hold an End-of-Phase 2 meeting with the FDA in December to design the Phase 3 registrational AUD program, the key near-term step for this indication. This adds detail to the positive topline announced in July 2026 and comes alongside the ongoing Phase 3 PERFORMA MASH trial and the fully enrolled RESTORE ALD study.
At the time of this announcement, ALT was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.3M. The 52-week trading range was $1.91 to $6.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.